Diasome Pharmaceuticals Adds Diabetes Experts to Board of Directors

Arthur H. Rubenstein and G. Alexander Fleming to Provide Strategic Direction for
Continued Growth
CONSHOHOCKEN, Pa.--(Business Wire)--
Diasome Pharmaceuticals, Inc., a clinical stage diabetes therapeutics company,
today announced the addition of Arthur H. Rubenstein, MBBCh, and G. Alexander
(Zan) Fleming, MD, to the company`s Board of Directors.

"Arthur currently chairs our Scientific Advisory Board and has been closely
associated with the development of HDV-Insulin for years," says Len Rosenberg,
PhD, RPh, President of Diasome. "We are also pleased to have Zan join our Board,
and look forward to benefitting from his scientific and medical guidance as we
advance our diabetes development program."

Arthur H. Rubenstein, MBBCh, currently serves as the Executive Vice President of
the University of Pennsylvania for the Health System and the Dean of the
University of Pennsylvania School of Medicine. He has previously served as the
Dean and CEO of the Mount Sinai School of Medicine in New York, and as the
Chairman of the Department of Medicine at the University of Chicago. Dr.
Rubenstein is an accomplished physician, diabetes researcher and academic
leader, and author of more than 350 publications.

G. Alexander Fleming, MD, is President and CEO of Kinexum and co-founder and
Chairman of Exsulin Corporation. Board certified in internal medicine and
endocrinology and metabolism, he completed his medical training and was a
researcher at Emory University, Vanderbilt University and National Institutes of
Health. Dr. Fleming was a Senior Medical Officer at FDA`s Division of Metabolic
and Endocrine Drug Products where he was responsible for the approval of many of
the current diabetes treatments on the market today.

"Both Arthur and Zan have had remarkable careers in the diabetes field and bring
years of invaluable experience to the team at Diasome," says David R. King,
Chairman of the Board at Diasome and Venture Partner at Quaker BioVentures. "We
are proud to welcome them to our Board of Directors."

Rubenstein and Fleming join the six current members of Diasome`s Board of
Directors: Chairman David King; Richard Caruso, PhD; Brenda Gavin, DVM, MBA; W.
Blair Geho, MD, PhD; Devang Kantesaria, MD; and Len Rosenberg, PhD.

About Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is a venture-backed biopharmaceutical company
focused on novel insulin-based therapies for the improved treatment of diabetes.
The Company was formed in late 2004 and has completed multiple Phase II human
studies of HDV-Insulin, its proprietary insulin targeting system. Diasome uses a
unique, nano-technology based cell targeting system to preferentially deliver
insulin to the hepatocytes in the liver. This technology has led to the
development of Oral HDV-Insulin, an advanced oral delivery system for insulin.
For more information, please visit Diasome`s website at www.diasome.com.

Diasome Pharmaceuticals
Press contact:
Gregory FCA
Theresa Murray, 610-642-8253 x164
Theresa@GregoryFCA.com

Copyright Business Wire 2009